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Abstract
Background: Although adiponectin levels have been reported to be correlated with albuminuria, this issue remains
unresolved in non-diabetic hypertensive subjects, particularly when urinary adiponectin is considered.
Methods: Urinary adiponectin levels were examined using an enzyme-linked immunosorbent assay in 229
participants. who used olmesartan as a hypertensive agent. Their albuminuria levels were measured for 16 weeks
after randomization and initiation of conventional or intensive diet education. Linear or logistic regression models
were applied, as appropriate, to explore the relationship with albuminuria itself or its response after the
intervention.
Results: Urinary adiponectin levels were positively related to baseline albuminuria level (r = 0.529). After adjusting
for several covariates, the adiponectin level was associated with the albuminuria level (β = 0.446). Among the 159
subjects with baseline macroalbuminuria, the risk of consistent macroalbuminuria (> 300 mg/day) at 16 weeks was
higher in the 3rd tertile of adiponectin than in the 1st tertile (odds ratio = 6.9), despite diet education. In contrast,
among all subjects, the frequency of the normoalbuminuria achievement (< 30 mg/day) at 16 weeks was higher in
the 1st tertile than in the 3rd tertile (odds ratio = 13.0).
Conclusions: Urinary adiponectin may be a useful biomarker for albuminuria or its response after treatment in
non-diabetic hypertensive patients.
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Background
Adiponectin, an adipokine, has several benefits related
to its insulin-sensitizing, anti-inflammatory, and anti-
atherosclerotic effects [1]. This peptide has primarily
been studied in certain disease subsets, such as meta-
bolic syndrome, obesity, and diabetes mellitus [2], and
this trend may have occurred because adiponectin is se-
creted by adipocytes. Recently, the role of adiponectin in
other types of kidney disease (e.g., non-diabetic kidney
disease) was discussed [3, 4]. The correlation between
adiponectin and non-diabetic kidney disease is plausible
because the pathophysiology in most kidney diseases is
based on inflammation [5], and some kidney diseases are
strongly attributable to the spectrum of obesity-related
diseases [6]. Additionally, the direct effect of adiponectin
on the kidney, as observed in experimental studies, sup-
ports this relationship [7].
Previous clinical studies have revealed that the blood
concentration of adiponectin is related to kidney injury,
including albuminuria. With the beneficial effect of adipo-
nectin in mind, low blood adiponectin potentially serves
as a biomarker for a high risk of albuminuria [8]. However,
the opposite relationship between them has been docu-
mented in certain types of disease, such as type 1 diabetes
[9]. Additional paradoxical findings where the blood adi-
ponectin level is higher in patients with chronic kidney
disease or end-stage renal disease than in counterpart sub-
jects further complicate our understanding [10]. Although
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the adiponectin feedback mechanism or dependent rela-
tionship with other mediators may be responsible for the
inconsistent results, it is not easy to measure blood adipo-
nectin as a biomarker across several disease subsets.
In contrast to blood adiponectin, a positive correlation
between urinary adiponectin and albuminuria has been
consistently demonstrated in previous studies. However,
it is too early to determine whether urinary adiponectin
is a consistent biomarker for the risk of albuminuria be-
cause most studies included diabetic patients [11], and
the counterpart studies including non-diabetic patients
are scarce, had low sample sizes, or were restricted to
only one disease subtype [3, 12, 13]. Here, we first ad-
dressed the relationship between urinary adiponectin
and albuminuria in a prospective cohort of non-diabetic
hypertensive patients. Then, the issue of whether an in-
dividual’s baseline level of urinary adiponectin can pre-
dict clinically implicated albuminuria after 16 weeks was
addressed.
Methods
Participants and data collection
The study protocol complies with the Declaration of
Helsinki and received full approval from the institutional
review board at Seoul National University Hospital (no.
H-1111-089-387). The present study was prospectively
conducted along with the study of ESPECIAL (Effects of
Low Sodium Intake on the Antiproteinuric Efficacy of
Olmesartan in Hypertensive Patients with Albuminuria;
clinicaltrials.gov-No: NCT01552954), which enrolled 245
non-diabetic hypertensive patients using a randomization
protocol [14]. All of the patients who participated in the
present study provided written informed consent and
agreed with the following protocol. First, 312 patients
were screened from the outpatient clinics of 7 centers in
Korea between March 2012 and March 2013. All pa-
tients fulfilled the following inclusion criteria: 19–75
years old; the use of antihypertensive medication or a
diagnosis of hypertension; estimated glomerular filtra-
tion rate ≥ 30 mL/min/1.73 m2, which was calculated
with the Modification of Diet in Renal Disease Study equa-
tion; random urine albumin-to-creatinine ratio ≥ 30 mg/g
creatinine more than two times with a ≥ 1-week interval in
the last 6 months; and an ability and willingness to provide
written informed consent. The exclusion criteria were as
follows: uncontrolled hypertension (blood pressure > 160/
110 mmHg); pregnancy; serum potassium > 5.5 mEq/L;
malignancy; diagnosis of cardiovascular disease within the
last 6 months; contraindication to angiotensin II receptor
blockers; diabetes mellitus; and continuous users of steroids
or other immunosuppressive agents. This screening was
conducted 8 weeks prior to study initiation.
After screening, all participants had to stop the use of
blocking agents of the renin angiotensin system and
diuretics, or were switched to antihypertensive agents
of different categories until the initiation of the study.
From the time of the study initiation, participants were
prescribed olmesartan medoxomil (Daewoong Pharma-
ceutical Co. Ltd./Daiichi Sankyo Korea Co. Ltd., Seoul,
Korea) at 40 mg, once per day for 16 weeks, at which
time the study ended. Additionally, participants were
randomly assigned to either conventional education or
intensive education for a low-salt diet because the ori-
ginal aim of the study was to assess the proteinuria-
lowering effects of intensive education in non-diabetic
patients with olmesartan.
At the time of study initiation, clinical and laboratory
parameters were obtained, including age, sex, weight,
height, blood pressure, histories of dyslipidemia and car-
diovascular disease (in adherence to the inclusion criteria),
smoking, exercise, the use of medications including beta
blockers, calcium channel blockers, statins, and antiplate-
let agents, and several blood (hemoglobin, cholesterol, uric
acid, and creatinine) and urine (sodium and albumin)
findings. The body mass index was calculated as [weight
(kg)/height (m2)]. Additionally, participants were asked to
collect 24-h urine samples to assess albuminuria at 8 and
16 weeks.
Some of the additional urine samples (n = 229) were
stored in a freezer at −70 °C for future measurement of
urinary adiponectin, with informed consent from the par-
ticipants. Total urinary adiponectin concentrations were
measured in duplicates using a highly sensitive enzyme-
linked immunosorbent assay (BioVendor, Brno, Czech
Republic), according to the manufacturer’s protocol. Urin-
ary adiponectin levels were adjusted for urinary creatinine
concentration.
Statistical analysis
All of the analyses and calculations were performed using
STATA software (version 12.0, StataCorp LP, College
Station, TX, USA). The data are presented as the mean ±
standard deviations for continuous variables and as propor-
tions for categorical variables. Based on variable distribu-
tions using histograms, the variables with non-normal
distributions are expressed as the median (interquartile
ranges). The chi-squared test was used to compare categor-
ical variables. Comparisons between normally distributed
continuous variables were performed using an analysis of
variance or a post-hoc analysis of the least significant differ-
ence, according to the number of comparison groups.
Comparisons between non-normally distributed continuous
variables were performed by either the Kruskal-Wallis test
or the Mann–Whitney U test, depending on the number of
comparison groups. The relationship between adiponectin
and albuminuria as continuous variables was assessed using
Pearson’s correlation and linear regression analyses. Stepwise
logistic regression models were tested to further examine
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the risks of macroalbuminuria (24-h albumin > 300 mg/day)
or the disappearance of albuminuria (normoalbuminuria;
24-h albumin < 30 mg/day) according to the tertiles of adi-
ponectin levels as follows: model 1, unadjusted for any co-
variate; model 2, adjusted for covariates with P < 0.1 in the
univariate analysis; and model 3, adjusted for all of the co-
variates. To account for a possible nonlinear relationship
with the outcomes, we also applied the fractional polyno-
mials method and showed the relationship as a fitted curve
[15]. A P value less than 0.05 was considered significant.
Results
Baseline characteristics
The baseline characteristics of the patients are shown
and compared among the groups based on the urinary
adiponectin level in Table 1. For the 229 subjects, the
mean age was 50 years. All of the subjects were of Asian
descent. The urinary adiponectin levels were different
among the tertile groups with regard to several charac-
teristics, including age, sex, smoking, exercise, statin use,
hemoglobin, kidney function, and albuminuria. Intensive
diet education was conducted less frequently in the sec-
ond tertile group than in the other tertiles. All of the
participants were examined for albuminuria at 8 and
16 weeks.
Correlation between urinary adiponectin and albuminuria
We first examined the relationship between urinary adipo-
nectin and albuminuria at the time of study initiation
(0 week). As shown in Fig. 1, the urinary adiponectin level
was positively related to the albuminuria level (r = 0.529;
P < 0.001). The Lowess line supported the linear relation-
ship between urinary adiponectin and albuminuria. After
adjusting for covariates, the adiponectin level was associ-
ated with the albuminuria level (β = 0.446; P < 0.001). To
determine the odds ratio (OR) of macroalbuminuria at
Table 1 Baseline characteristics of the study subjects
Urinary adiponectin
Variables Total (n = 229) 1st tertile (n = 76) 2nd tertile (n = 77) 3rd tertile (n = 76) P
Age (years) 49.5 ± 13.33 46.1 ± 14.29 51.2 ± 11.51* 51.2 ± 13.56* 0.022
Male (%) 49.8 64.5 40.3** 44.7* 0.006
Body mass index (kg/m2) 25.4 ± 3.81 25.5 ± 4.05 25.3 ± 3.63 25.4 ± 3.78 0.956
Mean blood pressure (mmHg) 105.6 ± 9.35 104.7 ± 9.07 104.8 ± 8.94 107.3 ± 9.90 0.161
Dyslipidemia (%) 56.6 47.9 64.4* 57.5 0.132
History of cardiovascular disease (%) 3.5 2.6 5.2 2.7 0.614
Current smoking (%) 12.2 7.9 7.8 21.1* 0.016
Regular exercise (%) 52.4 56.6 59.7 40.8 0.043
Intensive diet education (%) 48.5 56.6 33.8** 55.3 0.007
Medication (%)
Beta blocker 35.4 32.9 31.2 42.1 0.316
Calcium channel blocker 93.0 92.1 94.8 92.1 0.751
Statin 48.5 35.5 55.8* 53.9* 0.021
Antiplatelet agent 43.7 40.8 41.6 48.7 0.556
Blood findings
Hemoglobin (g/dL) 14.0 ± 1.71 14.4 ± 1.60 14.0 ± 1.66 13.6 ± 1.77*** 0.009
Cholesterol (mg/dL) 183.8 ± 35.27 181.8 ± 33.49 183.4 ± 35.09 186.3 ± 37.42 0.722
Uric acid (mg/dL) 6.4 ± 1.80 6.3 ± 1.80 6.1 ± 1.65 6.7 ± 1.93 0.192
Creatinine (mg/dL) 1.1 ± 0.41 1.0 ± 0.29 1.1 ± 0.39 1.3 ± 0.49*** <0.001
eGFR (ml/min/1.73 m2) 79.9 ± 24.62 88.9 ± 21.61 80.4 ± 21.89* 70.4 ± 26.75*** <0.001
Urine findings
Adiponectin (μg/g creatinine) 34.5 (15.0–86.8) 11.2 (3.9–15.0) 34.5 (25.9–46.6)*** 128.6 (86.5–202.9)*** <0.001
24-h sodium (mEq/day) 155.1 ± 68.94 162.1 ± 77.81 145.9 ± 55.61 157.5 ± 71.54 0.328
24-h albumin (mg/day) 550.0 (241.4–1286.1) 259.4 (134.3–517.2) 501.0 (268.0–1227.4)*** 1317.0 (660.9–2419.5)*** <0.001
Comparisons were evaluated using the chi-squared test for categorical variables, the ANOVA test for normally distributed continuous variables (post hoc analysis
of LSD between two groups), and the Kruskal-Wallis test for non-normally distributed continuous variables (Mann–Whitney U test between two groups). The 1st
tertile group served as a reference for comparison between two groups
*P < 0.05; **P < 0.01; ***P < 0.001
eGFR, estimated glomerular filtration rate
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baseline, stepwise logistic regression models were used
(Table 2). The risk of macroalbuminuria increased de-
pending on the tertiles of urinary adiponectin, regardless
of the effects of the covariates.
Risk of consistent macroalbuminuria according to
adiponectin level
At the time of the study initiation, a total of 159 subjects
(69.4 %) had baseline macroalbuminuria. After conven-
tional or intensive diet education, the proportion of macro-
albuminuria decreased substantially. Among these subjects,
31.4 % and 43.4 % of them recovered from macroalbumi-
nuria at 8 and 16 weeks, respectively. We categorized the
trend of macroalbuminuria according to the tertiles of urin-
ary adiponectin (Table 3). At 16 weeks, more than half of
the subjects in the 1st tertile group achieved a recovery
from macroalbuminuria, whereas few subjects in the 3rd
tertile recovered. We initially explored the non-linear rela-
tionship between urinary adiponectin and the risk of con-
sistent macroalbuminuria at 8 and 16 weeks (Fig. 2). The
trend in this figure showed that the risk of consistent
macroalbuminuria increased according to the increase in
urinary adiponectin levels. Subsequently, the unadjusted
and adjusted ORs of consistent 16-week macroalbuminuria
were higher in the 3rd tertile than in the 1st tertile group
(Table 4). The analysis of 8-week macroalbuminuria had a
similar trend (see Additional file 1).
Additionally, we examined the predictability of nor-
moalbuminuria after treatment. At 8 and 16 weeks, al-
buminuria disappeared in 4.8 % and 9.2 % of participants,
respectively. Figure 3 shows the inverse relationship be-
tween the urinary adiponectin level and the likelihood of
subsequent normoalbuminuria. We calculated the un-
adjusted and adjusted ORs of the 16-week outcome after
assigning a reference to the 3rd tertile (Table 4). As a re-
sult, the subjects with low adiponectin levels achieved nor-
moalbuminuria more frequently than did the subjects
with high adiponectin levels. For the 8-week outcome, nei-
ther a non-linear relationship nor ORs could be calculated
because of the low number of cases attaining normoalbu-
minuria at 8 weeks, and there were no such cases in the
3rd tertile group.
Fig. 1 Scatter plot with the linear (black) and Lowess (red) regression curves between urinary adiponectin and the baseline 24-h albumin level
Table 2 Odds ratio of macroalbuminuria according to the tertiles of urinary adiponectin
Model 1 Model 2 Model 3
Adiponectin group OR (95 % CI) P OR (95 % CI) P OR (95 % CI) P
1st tertile 1 (Reference) 1 (Reference) 1 (Reference)
2nd tertile 3.3 (1.68–6.47) 0.001 3.9 (1.68–9.02) 0.002 4.3 (1.72–10.54) 0.002
3rd tertile 12.2 (4.95–29.93) < 0.001 13.8 (4.77–40.21) < 0.001 13.8 (4.34–43.62) < 0.001
Model 1: unadjusted for any covariate
Model 2: adjusted for age, sex, dyslipidemia, smoking, exercise, diet education, statin, hemoglobin, and estimated glomerular filtration rate
Model 3: adjusted for all the covariates
OR, odds ratio; CI, confidence interval
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Discussion
Albuminuria has clinical implications for both cardiovascu-
lar and non-cardiovascular mortality. Previous studies have
investigated whether adiponectin predicts albuminuria or
its change. However, most of these studies used blood adi-
ponectin, and the few studies that used urinary adiponectin
included diabetic subjects alone or had a small sample size.
The present study determined the relationship in a non-
diabetic hypertensive cohort and supports the results ob-
served in the diabetic patients included in other studies.
Furthermore, urinary adiponectin was a strong predictor of
treatment response (i.e., the reduction of albuminuria by
diet education in the present trial). Based on these results,
urinary adiponectin can be used as a biomarker of albu-
minuria or its trend in hypertensive patients without
diabetes.
Several investigational studies have established the dir-
ect effect of adiponectin on the kidney. Ohashi et al.
compared albuminuria between adiponectin-knockout
and wild-type mice after subtotal nephrectomy [16]
found that albuminuria was increased to a greater extent
in the knockout model compared with the wild-type
model. Additionally, the authors found that the markers,
such as oxidative stress, inflammation, and fibrosis, were
different between the models and suggested that adipo-
nectin contributes to kidney injury via these factors.
Using adiponectin-knockout mice, Sharma et al. further
focused on the adiponectin-stimulated 5’ adenosine
monophosphate-activated protein kinase (AMPK) of
podocytes, and the subsequent stabilization of glomeru-
lar permeability and the reduction of oxidant stress [7].
These subsequent changes were identified with zonula
occludens-1 and nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase, respectively. The benefi-
cial role of adiponectin was also confirmed in other
in vivo models [17, 18] and in other kidney tissues, such
as the tubule and vessel [12, 17, 19].
When the direct effect of adiponectin is considered, it
is possible to observe a strong relationship between adi-
ponectin and albuminuria in human studies. However,
the relationship with blood adiponectin is complicated
and can vary according to kidney state or diabetic type
[8–10]. Although the reason for the complicated rela-
tionship has not been fully explored, this feature can
affect the other associations, such as cardiovascular mor-
bidity and mortality. As a result, some studies have
found no correlation between blood adiponectin and
cardiovascular markers [20]. In contrast, one study re-
vealed an inverse U-shaped relationship between blood
adiponectin and all-cause mortality in patients with end-
stage renal disease [21]. In addition to the non-invasive
nature of urine sampling, urinary adiponectin has an ad-
vantage over blood adiponectin because it is positively and
consistently related to the albuminuria level [3, 11–13].
However, it is too early to consider urinary adiponectin a
successful biomarker of albuminuria because there are few
studies on this issue, particularly studies including non-
diabetic subjects. We believe the present results meet a
need related to this issue.
We did not separate the molecular isoforms of adipo-
nectin. Some reports have suggested that high molecular
weight adiponectin is more reliable than the low molecu-
lar weight isoform in predicting outcomes [22]. However,
these reports have mainly concerned blood adiponectin,
Table 3 Trends of albuminuria according to the urinary adiponectin levels in the participants with baseline macroalbuminuria
8 weeks 16 weeks
Goal Adiponectin group Achieved [n (%)] Not achieved [n (%)] Achieved [n (%)] Not achieved [n (%)]
Albuminuria ≤ 300 mg/day 1st tertile (n = 34) 19 (55.9) 15 (44.1) 22 (64.7) 12 (35.3)
2nd tertile (n = 56) 20 (35.7) 36 (64.3) 28 (50.0) 28 (50.0)
3rd tertile (n = 69) 11 (15.9) 58 (84.1) 19 (27.5) 50 (72.5)
Fig. 2 Fitted curve of the macroalbuminuria risk at 8 weeks (a) and 16 weeks (b), according to the urinary adiponectin level
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not the urinary counterpart. Adiponectin exists largely as
the low molecular weight isoform in urine [12], and there
are reports that only low molecular weight adiponectin,
and not the high molecular weight isoform, has anti-
inflammatory property [23].
Increased glomerular permeability due to podocyte in-
jury can induce the hyper-filtration of adiponectin into
urine. Monomeric and trimeric adiponectin (i.e., low mo-
lecular weight) have a molecular weight that is smaller
than or similar to that of albumin. Accordingly, urinary
adiponectin is likely to precede the onset of albuminuria.
The present study shows that urinary adiponectin can pre-
dict the response of albuminuria to a certain treatment. A
few studies have also found that the adiponectin level was
altered by treatment (i.e., angiotensin II receptor blockers)
and its response, although those studies used blood adipo-
nectin [24]. In view of the results achieved so far, both
blood and urinary adiponectin levels can be useful inde-
pendent biomarkers for the treatment response of albu-
minuria. As previously stated, urinary adiponectin is more
accessible than blood adiponectin because of the intrinsic
nature of the test and the consistent results that have been
observed across several diseases.
Although the present results are informative, this study
has some limitations. First, the study design, which in-
volves observing correlations, limits the drawing of con-
clusions based on causality. However, the main aim of the
present study was to determine whether urinary adiponec-
tin is a successful biomarker; thus, the current design does
not significantly hamper this aim. Second, the overall dur-
ation of treatment response (i.e., 8 and 16 weeks) was rela-
tively short. However, 58 % of the total participants (43 %
of participants with baseline macroalbuminuria) achieved
a reduction of macroalbuminuria at 16 weeks. This result
indicates that the treatment duration was sufficient to ob-
tain results for analysis. Third, we did not consider other
valuable parameters, such as patient compliance, weight
change, and the control of blood pressure in the following
course of study; these parameters might also affect pro-
teinuria and its response.
Table 4 Implication of urinary adiponectin as a predictor of clinical outcome
Model 1 Model 2 Model 3
16-week outcome Adiponectin group OR (95 % CI) P OR (95 % CI) P OR (95 % CI) P
Macroalbuminuria 1st tertile 1 (Reference) 1 (Reference) 1 (Reference)
2nd tertile 1.8 (0.76–4.41) 0.176 1.7 (0.65–4.68) 0.273 2.3 (0.80–6.86) 0.119
3rd tertile 4.8 (2.00–11.63) <0.001 5.0 (1.73–14.48) 0.003 6.9 (2.06–22.98) 0.002
Normoalbuminuria 1st tertile 16.9 (2.17–132.41) 0.007 16.5 (1.81–150.62) 0.013 13.0 (1.38–122.37) 0.025
2nd tertile 6.4 (0.76–54.74) 0.089 10.6 (1.05–107.46) 0.045 9.4 (0.89–99.42) 0.062
3rd tertile 1 (Reference) 1 (Reference) 1 (Reference)
Model 1: unadjusted for any covariate
Model 2: adjusted for age, sex, dyslipidemia, smoking, exercise, diet education, statin, hemoglobin, and estimated glomerular filtration rate
Model 3: adjusted for all the covariates
OR, odds ratio; CI, confidence interval
Fig. 3 Fitted curve of the achievement of normoalbuminuria at 16 weeks, according to the urinary adiponectin level
Han et al. BMC Nephrology  (2015) 16:123 Page 6 of 7
Conclusions
Urinary adiponectin was a strong predictor of albuminuria,
as previously found in other clinical settings. Furthermore,
it was correlated with the real response of albuminuria after
albuminuria reduction was implemented. Based on the re-
sults presented by our and other studies, urinary adiponec-
tin can be used as a biomarker for albuminuria. Because
albuminuria alone is not an accurate prognostic indicator
of several outcomes, additional studies are needed to ad-
dress whether urinary adiponectin has predictive power in
these outcomes.
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